Phosphoinositide signalling in cancer: beyond PI3K and PTEN

被引:322
|
作者
Bunney, Tom D. [1 ]
Katan, Matilda [1 ]
机构
[1] Inst Canc Res, Chester Beatty Labs, Sect Cell & Mol Biol, London SW3 6JB, England
关键词
PHOSPHOLIPASE-C-EPSILON; COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; 4-PHOSPHATASE TYPE-II; BREAST-CANCER; CELL-MIGRATION; MYELODYSPLASTIC SYNDROMES; ACTIN CYTOSKELETON; COLORECTAL-CANCER; TUMOR-SUPPRESSOR;
D O I
10.1038/nrc2842
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are numerous studies that suggest multiple links between the cellular phosphoinositide system and cancer. As key roles in cancer have been established for PI3K and PTEN-enzymes that regulate the levels of phosphatidylinositol-3,4,5-trisphosphate-compounds targeting this pathway are entering the clinic at a rapid pace. Several other phosphoinositide-modifying enzymes, including phosphoinositide kinases, phosphatases and phospholipase C enzymes, have been implicated in the generation and progression of tumours. Studies of these enzymes are providing new insights into the mechanisms and the extent of their involvement in cancer, highlighting new potential targets for therapeutic intervention.
引用
收藏
页码:342 / 352
页数:11
相关论文
共 50 条
  • [41] The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Schwartz, Sarit
    Carver, Brett S.
    Wongvipat, John
    Rodrik-Outmezguine, Vanessa
    Stanchina, Elisa D.
    Trigwell, Cath
    Barry, Simon
    Baselga, Jose
    Chandarlapaty, Sarat
    Scher, Howard I.
    Sawyers, Charles L.
    Rosen, Neal
    CANCER RESEARCH, 2014, 74 (19)
  • [42] PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
    Gonzalez-Angulo, Ana M.
    Ferrer-Lozano, Jaime
    Stemke-Hale, Katherine
    Sahin, Aysegul
    Liu, Shuying
    Barrera, Juan A.
    Burgues, Octavio
    Lluch, Ana M.
    Chen, Huiqin
    Hortobagyi, Gabriel N.
    Mills, Gordon B.
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (06) : 1093 - 1101
  • [43] PTEN and PI3K/AKT in non-small-cell lung cancer
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Angel Molina, Miguel
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    PHARMACOGENOMICS, 2015, 16 (16) : 1843 - 1862
  • [44] Targeting the PTEN/PI3K pathway: From mouse model to human cancer
    Wu, Hong
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [45] Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
    Prvanovic, Mirjana
    Nedeljkovic, Milica
    Tanic, Nasta
    Tomic, Tijana
    Terzic, Tanja
    Milovanovic, Zorka
    Maksimovic, Zlatko
    Tanic, Nikola
    LIFE-BASEL, 2021, 11 (11):
  • [46] The orchestrated signaling by PI3K? and PTEN at the membrane interface
    Kotzampasi, Danai Maria
    Premeti, Kyriaki
    Papafotika, Alexandra
    Syropoulou, Vasiliki
    Christoforidis, Savvas
    Cournia, Zoe
    Leondaritis, George
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 5607 - 5621
  • [47] MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway
    Li, Lihua
    Zhu, Xiongjie
    Shou, Tao
    Yang, Libo
    Cheng, Xiaozhen
    Wang, Jinting
    Deng, Lian
    Zheng, Yanfang
    MOLECULAR MEDICINE REPORTS, 2018, 17 (03) : 4003 - 4010
  • [48] PTEN and PI3K signaling in brain development and disease
    Baker, Suzanne J.
    CANCER RESEARCH, 2014, 74 (23)
  • [49] Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition
    Nussinov, Ruth
    Zhang, Mingzhen
    Tsai, Chung-Jung
    Jang, Hyunbum
    MOLECULAR CANCER RESEARCH, 2021, 19 (04) : 543 - 548
  • [50] Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
    Bertucci, Alexandre
    Bertucci, Francois
    Goncalves, Anthony
    CANCERS, 2023, 15 (05)